Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib vs Doxorubicin in Elderly Advanced Soft Tissue Sarcoma
NCT01861951Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Oct 2012
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of pazopanib in soft tissue sarcoma (STS) (2 arms), sponsored by Hannover Medical School. Primary endpoint: Progression-Free Survival. Started Oct 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01861951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861951.